IP Library Granted Patent US 7,402,299
Granted Patent B2
US 7,402,299 · App. 10/999,313 · Granted Jul 22, 2008

Intracorporeal medicaments for photodynamic treatment of disease

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,402,299
App. No.
10/999,313
Granted
Jul 22, 2008
Kind
B2
Abstract

New intracorporeal photodynamic medicaments and certain medical uses and methods for use of such photodynamic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection. In another preferred embodiment, such medicaments are produced in various formulations including liquid, semisolid, solid or aerosol delivery vehicles.

Claims (4)

1. A method of treating human tissue comprising:

applying an intracorporeal medicament comprising at least one halogenated xanthene into or proximate to said human tissue, wherein said halogenated xanthene is disodium 4,5,6,7-Tetrabromoerythrosin; and

illuminating said human tissue with light having a wavelength of between approximately 500 and 600 unm to activate said halogenated xanthene present within or proximate to said tissue.

2. The method of claim 1 wherein said human tissue comprises the skin, the mouth and digestive tract, the urinary and reproductive tracts, the respiratory tract, the circulatory system, the head and neck, the endocrine and lymphoreticular systems, connective tissue, tissue surfaces exposed during surgery, and tissue with microbial, viral, or fungal infection.

Assignments (17)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 24, 2018
From: DEES, H. CRAIG; SCOTT, TIMOTHY C.; WACHTER, ERIC A.; FISHER, WALTER G.; SMOLIK, JOHN
To: PHOTOGEN, INC.
Reel/Frame 045897/0083 →
SECURITY INTEREST Recorded Apr 10, 2018
From: PROVECTUS BIOPHARMACEUTICALS, INC.; PROVECTUS PHARMATECH, INC.; PROVECTUS BIOTECH, INC.; PURE-IFIC, INC.
To: MILLENNIUM TRUST CO. LLC
Reel/Frame 045489/0315 →
SECURITY INTEREST Recorded Apr 10, 2018
From: PROVECTUS BIOPHARMACEUTICALS, INC.; PROVECTUS PHARMATECH, INC.; PROVECTUS BIOTECH, INC.; PURE-IFIC, INC.
To: LARCEN, MARDELL
Reel/Frame 045489/0699 →
SECURITY INTEREST Recorded Apr 10, 2018
From: PROVECTUS BIOPHARMACEUTICALS, INC.; PROVECTUS PHARMATECH, INC.; PROVECTUS BIOTECH, INC.; PURE-IFIC, INC.
To: TROUT, JONH W.; TROUT, JOSH HUDSON
Reel/Frame 045877/0656 →
SECURITY INTEREST Recorded Apr 10, 2018
From: PROVECTUS BIOPHARMACEUTICALS, INC.; PROVECTUS PHARMATECH, INC.; PROVECTUS BIOTECH, INC.; PURE-IFIC, INC.
To: WACHTER, ERIC A.
Reel/Frame 045879/0779 →
SECURITY INTEREST Recorded Apr 10, 2018
From: PROVECTUS BIOPHARMACEUTICALS, INC.; PROVECTUS PHARMATECH, INC.; PROVECTUS BIOTECH, INC.; PURE-IFIC, INC.
To: TIMOTHY WILLIAMS REVOCABLE TRUST
Reel/Frame 045489/0193 →
SECURITY INTEREST Recorded Apr 9, 2018
From: PROVECTUS BIOPHARMACEUTICALS, INC.; PROVECTUS PHARMATECH, INC.; PROVECTUS BIOTECH, INC.; PURE-IFIC, INC.
To: SCOTT, TIMOTHY C.; SCOTT, LEIGH ANNE
Reel/Frame 045478/0270 →
SECURITY INTEREST Recorded Apr 9, 2018
From: PROVECTUS BIOPHARMACEUTICALS, INC.; PROVECTUS PHARMATECH, INC.; PROVECTUS BIOTECH, INC.; PURE-IFIC, INC.
To: FORTUNATO, PAUL M.; FORTUNATO, KATHLEEN E.
Reel/Frame 045478/0511 →
SECURITY INTEREST Recorded Apr 9, 2018
From: PROVECTUS BIOPHARMACEUTICALS, INC.; PROVECTUS PHARMATECH, INC.; PROVECTUS BIOTECH, INC.; PURE-IFIC, INC.
To: HANSEN, CHRIS; HANSEN, STEPHANIE
Reel/Frame 045480/0437 →
SECURITY INTEREST Recorded Apr 9, 2018
From: PROVECTUS BIOPHARMACEUTICALS, INC.; PROVECTUS PHARMATECH, INC.; PROVECTUS BIOTECH, INC.; PURE-IFIC, INC.
To: MORRIS, JEFFREY A.
Reel/Frame 045480/0690 →
SECURITY INTEREST Recorded Apr 9, 2018
From: PROVECTUS BIOPHARMACEUTICALS, INC.; PROVECTUS PHARMATECH, INC.; PROVECTUS BIOTECH, INC.; PURE-IFIC, INC.
To: SMITH, GREGORY LYNN
Reel/Frame 045480/0960 →
SECURITY INTEREST Recorded Apr 9, 2018
From: PROVECTUS BIOPHARMACEUTICALS, INC.; PROVECTUS PHARMATECH, INC.; PROVECTUS BIOTECH, INC.; PURE-IFIC, INC.
To: MILLENNIUM TRUST CO. LLC
Reel/Frame 046437/0748 →
SECURITY INTEREST Recorded Aug 9, 2017
From: PROVECTUS PHARMATECH, INC.; PROVECTUS BIOPHARMACEUTICALS, INC.
To: TED R. WATSON REVOCABLE TRUST
Reel/Frame 043244/0210 →
SECURITY INTEREST Recorded Aug 1, 2017
From: PROVECTUS PHARMATECH, INC.; PROVECTUS BIOPHARMACEUTICALS, INC.
To: PATRICIA F. BISCHOFF REVOCABLE TRUST
Reel/Frame 043156/0410 →
SECURITY INTEREST Recorded Jun 26, 2017
From: PROVECTUS PHARMATECH, INC.; PROVECTUS BIOPHARMACEUTICALS, INC.
To: TAUSK, SCOTT A.; TAUSK, SANDRA J.
Reel/Frame 042809/0755 →
SECURITY INTEREST Recorded Apr 21, 2017
From: PROVECTUS PHARMATECH, INC.; PROVECTUS BIOPHARMACEUTICALS, INC.
To: MORRIS, JEFFREY A.
Reel/Frame 042091/0421 →
SECURITY INTEREST Recorded Apr 4, 2017
From: PROVECTUS PHARMATECH, INC.; PROVECTUS BIOPHARMACEUTICALS, INC.
To: WACHTER, ERIC A.; CAL ENTERPRISES LLC
Reel/Frame 042188/0389 →